Elicio Therapeutics, Inc. ELTX
Set alert
At close · Oct 30
After hours · Oct 30, 7:57 PM ET
- YTD
- -78.89%
- 1 year
- -81.84%
- Open
- 1.74
- Prev close
- 1.75
- Mkt cap
- 45.51M
- Vol
- 183.88K
- Avg vol
- 313.34K
- EPS
- -2.16
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.66
- High
- 1.78
- Forward P/E
- -1.96
- Beta
- 0.00
- Short ratio
- 2.49
- Inst. own
- 5.82%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 4.92
- 200-d avg
- 5.97
- 1y target
- 9.50
News
-
3 days ago benzinga.com
Elicio Therapeutics To Demonstrate Data Of Two Poster Presentations For Its Phase 2 AMPLIFY-7P Trial Of Camupepimut , Expanded Antigen-Agnostic Intratumoral Application Of AMP-Adjuvant Platform At Society For Immunotherapy Of Cancer's Annual Meeting
Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that…
3 days ago globenewswire.com
Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting
Keynote/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancer Additional…
-
1 week ago benzinga.com
Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results At ESMO Congress 2026; Multiple Pre-Specified Subgroup Analyses Favored Camupepimut, Including Patients With And Without Detectable Baseline ctDNA; Encouraging Disease-Free Survival Outcomes Were Observed In Both ctDNA-Negative And ctDNA-Positive Patients
Elicio Therapeutics, Inc. (NASDAQ:ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced results
-
1 week ago benzinga.com
Elicio Therapeutics Presents Data From Its Phase 2 AMPLIFY-7P Trial Of Camupepimut At European Society For Medical Oncology Congress 2026
Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced results
1 week ago globenewswire.com
Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine
BOSTON, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for…
1 week ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics…
-
1 month ago benzinga.com
B. Riley Securities Maintains Buy on Elicio Therapeutics, Lowers Price Target to $8
B. Riley Securities analyst Mayank Mamtani maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and lowers the price target from $27 to $8.
1 month ago globenewswire.com
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
New pre-specified analyses from the randomized Phase 2 study will further characterize the clinical potential of ELI-002 7P (camupepimut) in adjuvant pancreatic cancer Findings are expected to inform…
2 months ago globenewswire.com
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
BOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for…
2 months ago globenewswire.com
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for…
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $23 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics (NASDAQ:ELTX) with a Buy and maintains $23 price target.
-
2 months ago benzinga.com
Elicio Therapeutics Q2 EPS $(0.43) Beats $(0.54) Estimate
Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.54) by 20.37 percent. This is a 34.85 percent increase over losses of…
2 months ago globenewswire.com
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor…
3 months ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. ("Elicio" or the "Company") (NASDAQ: ELTX). Such investors are advised…
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $2.5 million. Tvardi Therapeutics…
3 months ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. (“Elicio” or the “Company”) (NASDAQ: ELTX). Such investors are…
3 months ago globenewswire.com
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
BOSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for…
4 months ago benzinga.com
11 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's regular session. The market value of their outstanding shares is at $12.2 million. Liminatus Pharma…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 40.9% to $0.16 during Thursday's pre-market session. The market value of their outstanding shares is at $5.8 million. Stablecoin Development…
4 months ago globenewswire.com
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for…
4 months ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. (“Elicio” or the “Company”) (NASDAQ: ELTX). Such investors are…
4 months ago globenewswire.com
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for…
4 months ago businesswire.com
ELTX Investors Have Opportunity to Join Elicio Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $ELTX--ELTX Investors Have Opportunity to Join Elicio Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.
4 months ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. ("Elicio" or the "Company") (NASDAQ: ELTX). Such investors are…
4 months ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. (“Elicio” or the “Company”) (NASDAQ: ELTX). Such investors are…
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
4 months ago benzinga.com
Why Smith & Wesson Brands Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Smith & Wesson (SWBI) shares rose in pre-market trading after posting strong Q4 results, beating earnings and revenue estimates. Other gainers include LNKS, ADTX, and SPRO.
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
4 months ago benzinga.com
Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug
Elicio Therapeutics Inc. (NASDAQ:ELTX) stock is up on Wednesday as the company reported promising clinical observations regarding its ELI-002 7P treatment.
4 months ago globenewswire.com
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based…
4 months ago prnewswire.com
Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)
Elicio Therapeutics reported Q1 2026 results showing a widening net loss and zero revenue days before its lead clinical program failed -- investors who bought ELTX lost 72.5% in a single session. NEW…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
4 months ago benzinga.com
Elicio Therapeutics Pancreatic Cancer Study Disappoints
Elicio Therapeutics Inc. (NASDAQ:ELTX) stock is trading lower on Monday after disappointing results from its Phase 2 AMPLIFY-7P study of ELI-002 7P in patients with mutant KRAS-driven pancreatic…
4 months ago globenewswire.com
ELTX INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Elicio Therapeutics, Inc.
ATLANTA, June 15, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Elicio Therapeutics, Inc. (“Elicio” or the “Company”) (NASDAQ: ELTX) complied with federal securities laws. On…
4 months ago benzinga.com
Crude Oil Tumbles Over 5%; Empire State Manufacturing Index Falls In June
US stocks gain on peace agreement with Iran, Nasdaq up 2%, Dow up 1.1%, S&P 500 up 1.54%. Tech shares jump 2.8%, energy stocks fall 3.5%. Empire State manufacturing index drops to 5.7. Industrial…
4 months ago benzinga.com
Dow Jumps Over 600 Points Following US-Iran Peace Deal
US stocks rise on peace agreement with Iran, Dow up 600 points. Tech sector jumps, energy stocks down. Trump announces deal, oil futures decline.
-
4 months ago benzinga.com
10 Health Care Stocks Moving In Monday's Pre-Market Session
10 Health Care Stocks Moving In Monday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
1 year ago benzinga.com
Why INNOVATE Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket
Why INNOVATE Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition proposal to acquire 100% of equity of the company for $1.80 per…